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Abstract
Background Acute diarrhoea is a frequent health problem
in both travellers and residents that has a social and eco-
nomic impact. This study compared the efficacy and tol-
erability of two loperamide–simeticone formulations and a
Saccharomyces boulardii capsule as symptomatic
treatment.
Methods This was a prospective, randomised, single
(investigator)-blind, three-arm, parallel group, non-inferi-
ority clinical trial in adult subjects with acute diarrhoea at
clinics in Mexico and India, with allocation to a lop-
eramide–simeticone 2/125 mg caplet or chewable tablet
(maximum eight in 48 h) or S. boulardii (250 mg twice
daily for 5 days).
Outcome Measures The primary outcome measure was
the number of unformed stools between 0 and 24 h fol-
lowing the initial dose of study medication (NUS 0–24).
The secondary outcome measures were time to last
unformed stool (TLUS), time to complete relief of
diarrhoea (TCRD), time to complete relief of abdominal
discomfort (TCRAD) and the subject’s evaluation of
treatment effectiveness. Follow-up endpoints at 7 days
were feeling of complete wellness; stool passed since final
study visit; and continued or recurrent diarrhoea.
Subjects In this study, 415 subjects were randomised to
either a loperamide–simeticone caplet (n = 139), lop-
eramide–simeticone chewable tablet (n = 139) or
S. boulardii capsule (n = 137) and were included in the
intention-to-treat analysis.
Results With regards to mean NUS 0–24, the lop-
eramide–simeticone caplet was non-inferior to lop-
eramide–simeticone tablets (3.4 vs. 3.3; one-sided 97.5 %
confidence interval B0.5), with both significantly lower
than S. boulardii (4.3; p\ 0.001). The loperamide–
simeticone groups had a shorter median TLUS [14.9 and
14.0 vs. 28.5 h (loperamide–simeticone caplet and chew-
able tablet groups, respectively, vs. S. boulardii);
p\ 0.001], TCRD (26.0 and 26.0 vs. 45.8 h; p\ 0.001)
and TCRAD (12.2 and 12.0 vs. 23.9 h; p\ 0.005) than
S. boulardii. Treatment effectiveness for overall illness,
diarrhoea and abdominal discomfort relief was greater
(p\ 0.001) in the loperamide–simeticone groups than with
S. boulardii. At 7-day follow-up most subjects reported
passing stool at least once since the final study visit (lop-
eramide–simeticone caplet 94.1 %, loperamide–simeticone
chewable tablet 94.8 %, S. boulardii 97.0 %), did not
experience continued or recurrent diarrhoea [loperamide–
simeticone caplet 3.7 % (p\ 0.03 vs. S. boulardii), lop-
eramide–simeticone chewable tablet 3.7 %, S. boulardii
5.7 %] and felt completely well [loperamide–simeticone
caplet 96.3 % (p\ 0.02 vs. S. boulardii), loperamide–
simeticone chewable tablet 96.3 % (p\ 0.02 vs.
S. boulardii), S. boulardii 88.6 %]. All treatments were
well-tolerated with few adverse events.
This study has been previously presented at a scientific meeting:
Clinical study comparing loperamide–simeticone and the probiotic
Saccharomyces boulardii in acute diarrhoea. United European
Gastroenterology (UEG) Week; 23–27 October 2010; Barcelona,
Spain.
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Conclusions The loperamide–simeticone caplet was non-
inferior to the original loperamide–simeticone chewable
tablet formulation; both formulations can be expected to
demonstrate similar clinical efficacy in the relief of
symptoms of acute diarrhoea. Both loperamide–simeticone
formulations were superior to the S. boulardii capsule in
the primary and secondary endpoints.
Clinical Trial Registration ClinicalTrials.gov identifier
NCT00807326.
Key Points
The loperamide–simeticone caplet formulation was
demonstrated to be non-inferior to the original
chewable tablet formulation; both formulations can
be expected to demonstrate similar clinical efficacy
in the relief of symptoms of acute diarrhoea in
adults.
The Saccharomyces boulardii capsule used at the
approved dose was significantly less effective than
the loperamide–simeticone formulations in relieving
the symptoms of acute diarrhoea in adults.
S. boulardii may have more of a role in diarrhoea in
children, more persistent diarrhoea or diarrhoea
prevention.
1 Introduction
Acute diarrhoea is a common diagnosis in general practice,
although most affected individuals do not consult a
physician. It has been estimated that the annual rate of
acute diarrhoea in industrialised countries averages
0.5–2 episodes per person per year [1]. Many episodes of
diarrhoea are travel-related; traveller’s diarrhoea (TD) has
an attack rate from 20 to over 60 % depending on the
destination [2], and it has been estimated that the illness
affects 15–20 million people annually [3]. Although in
most cases self-limiting, TD causes substantial disruption
by interfering with travel itineraries, business opportunities
and tourist industry revenues. Acute uncomplicated diar-
rhoea is commonly managed in travellers and residents
alike with adequate hydration and self-medication.
Loperamide is an effective antidiarrhoeal agent with
antimotility and antisecretory actions, and is the preferred
symptomatic treatment for diarrhoea for most non-febrile,
non-dysenteric cases [4–7]. A loperamide–simeticone
combination chewable tablet is widely available and is
indicated for the symptomatic treatment of acute diarrhoea
associated with gas-related abdominal discomfort,
including bloating, cramping or flatulence. Two double-
blind, randomised placebo-controlled studies demonstrated
that a loperamide–simeticone combination chewable tablet
was significantly more effective in the relief of acute
diarrhoea than either loperamide or simeticone alone or
placebo over a 48-h study period [8, 9]. Both studies were
conducted in Mexico and included mixed populations of
international travellers and local residents. These studies
suggest that loperamide and simeticone may act synergis-
tically to enhance efficacy in acute diarrhoea, possibly
explained by modified intestinal kinetics of loperamide
when formulated with simeticone [10]. A loperamide–
simeticone caplet (capsule-shaped tablet) formulation was
subsequently developed, but there are no clinical data on
the efficacy of this formulation. More recently, a compar-
ison of loperamide–simeticone with loperamide alone
using a mannitol model of secretory diarrhoea demon-
strated that both forms of loperamide significantly reduced
small bowel water content, but that the loperamide–
simeticone combination also significantly reduced ascend-
ing colon water content [11]. This finding is consistent with
the greater clinical efficacy found with the combination,
although a higher than usual dose was used in this study.
Saccharomyces boulardii is a non-pathogenic probiotic
yeast used first in France to treat diarrhoea in the beginning
of the 1950s, and is now widely available worldwide in a
lyophilised form. The antidiarrhoeal effect of lyophilised
S. boulardii has been investigated in various forms of
diarrhoeal diseases, including antibacterial-associated and
acute infectious diarrhoea in adults and children, with
evidence of efficacy [12–21]. Although the exact mecha-
nism by which S. boulardii might exert its activity remains
unclear, several possible mechanisms have been proposed,
including inhibition of pathogen adhesion, strengthening of
enterocyte tight junctions, neutralisation of bacterial viru-
lence factors and enhancement of the mucosal immune
response [13].
The aim of this study was to compare the efficacy and
safety of two formulations of loperamide–simeticone
combination in the treatment of acute diarrhoea in adults,
on the basis of a therapeutic non-inferiority design; the
study also compares the loperamide–simeticone combina-
tions versus a S. boulardii probiotic capsule.
2 Patients and Methods
2.1 Study Design
This was a prospective, randomised, single (investigator)-
blind, three-arm, parallel group, non-inferiority clinical
trial conducted in accordance with the principles of the
1964 Declaration of Helsinki and later amendments, and
364 J. Cottrell et al.
with applicable Good Clinical Practice (GCP) guidelines.
Local regulatory requirements were followed, and the
study protocol and associated documents were reviewed
and approved by the Ethics Committees for each partici-
pating site. The study was registered on ClinicalTrials.gov
(NCT00807326).
2.2 Participants
Four clinical sites in Mexico and two in Goa, India par-
ticipated in the study. Publicity posters and cards were used
to raise awareness of the study among both travellers and
local residents. Potentially eligible subjects were invited to
attend either outreach clinics or the investigator sites for
assessment. Male or female subjects aged 18 years or over
were recruited if they had symptoms of acute diarrhoeal
illness with onset during the prior 48 h, a minimum of
three unformed stools in the 24 h before study entry with
the most recent stool unformed, and with abdominal dis-
comfort within the prior 4 h. All subjects provided written
informed consent prior to inclusion in the study.
Exclusion criteria were requiring hospital admission,
parenteral hydration or antibacterial therapy; axillary
temperature[38.2 C or oral temperature[38.6 C; his-
tory or clinical evidence of gross blood or pus in stool;
orthostatic hypotension; unable to take medication and
fluids by mouth; chronic gastrointestinal disease, hepatic or
renal insufficiency, or other significant medical condition;
immunodeficiency; antibacterials, oral antifungals, quini-
dine or ritonavir within 7 days, antidiarrhoeal or prokinetic
drugs, antiflatulents, probiotics or bismuth salts within
48 h, or any analgesic within 6 h prior to study entry; use
of opiates; hypersensitivity to study medication; pregnant
or breast-feeding; and unable to comply with the study
requirements.
2.3 Intervention
Eligible subjects providing informed consent were
sequentially assigned to study medication according to a
randomised schedule. The subjects were provided with
either:
(A) Loperamide–simeticone 2/125 mg capsule-shaped
tablet (caplet), in total eight caplets (Imodium Plus
Caplet, McNeil Products Ltd., Maidenhead, UK); or
(B) Loperamide–simeticone 2/125 mg chewable tablets,
in total eight tablets (Imodium Plus chewable
tablet, McNeil Products Ltd., Maidenhead, UK); or
(C) S. boulardii 250 mg capsules, in total ten capsules
(Perenterol Forte 250 mg capsules, MEDICE
Arzneimittel Pu¨tter GmbH & Co. KG. Iserlohn,
Germany).
For treatments A and B, two caplets or chewable tablets
were taken initially at the investigator site, followed sub-
sequently by one caplet/tablet after each unformed stool,
with a maximum of four caplets/tablets in a 24-h period,
for up to 48 h. For treatment C, subjects were asked to take
one capsule twice a day for 5 days.
Subjects recorded their symptoms, time and consis-
tency of bowel movements, and time of study medica-
tion administration for the 48-h period after their initial
dose in a study diary. Stool consistency was rated
according to a 3-point scale of formed, soft or liquid.
Subjects rated the intensity of their gas-related abdom-
inal discomfort from 0 (absent) to 4 (severe) hourly over
the first 4 h of the study, and at 8, 12, 18, 24, 36 and
48 h after the initial dose. At 12, 24 or 48 h or at the
time of discontinuation from the study, subjects recorded
if and when they experienced complete relief from their
diarrhoea. At 48 h or at the time of discontinuation from
the study, subjects recorded an overall evaluation of
treatment effectiveness, as well as overall evaluations of
the treatment effectiveness in relieving gas-related
abdominal discomfort and diarrhoea (separately) on a
5-point scale ranging from 0 (poor) to 4 (excellent).
Adverse events were recorded throughout the study
using patient diaries.
After 48 h in the study and within 72 h of entry, each
patient returned to the study site for a second visit, at which
time the patient diary was returned; at this visit, the entire
diary was reviewed with the patient to ensure that all
required information had been recorded and any reported
adverse events were noted.
Subjects were issued with cards for follow-up questions
at 7 days after baseline and asked whether they would
prefer to respond by return of the card, email or telephone
interview. Subjects were asked the following questions:
‘‘Have you passed stool since your final study visit?’’; ‘‘Has
your diarrhoea continued or returned since your final study
visit?’’; ‘‘If diarrhoea has continued or returned, how many
unformed (soft or liquid) stool have you passed since your
final study visit?’’; and ‘‘Do you feel completely well fol-
lowing your diarrhoea illness?’’.
2.4 Endpoints
The primary endpoint was the number of unformed stools
passed between 0 and 24 h following the initial dose of
study medication (NUS 0–24).
Secondary endpoints included time to last unformed
stool (TLUS), time to complete relief of diarrhoea (TCRD),
time to complete relief of abdominal discomfort (TCRAD)
and subject’s evaluation of treatment effectiveness for
overall illness relief, diarrhoea relief and abdominal
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discomfort relief, and number and severity of reported
adverse events during the study.
The follow-up endpoints at 7 days were feeling com-
pletely well following diarrhoea illness; stool passed at
least once between study visit 2 and follow-up; and con-
tinued or recurrent diarrhoea between final study visit and
follow-up.
2.5 Sample Size
Sample size estimation was based on NUS 0–24, with an
assumed standard deviation of 1.3, no expected mean
treatment difference for the two loperamide–simeticone
groups and a pre-specified non-inferiority margin of 0.5. If
the number of evaluable primary endpoint data in each
group was 108, a two-group one-sided t-test of significance
level of 0.025 aiming to show non-inferiority of caplets
relative to tablets had 80 % power to reject the null
hypothesis that the mean treatment difference (caplets
minus tablets) in NUS 0–24 was greater than the non-in-
feriority margin of 0.5 versus the alternative hypothesis
that the mean treatment difference was B0.5. Allowing for
drop-outs and for non-evaluable data, a minimum sample
size of 125 per group was required.
2.6 Randomisation and Blinding
Subjects were randomly assigned to one of the
three treatment groups based on a computer-generated
randomisation schedule prepared by the sponsor before the
study. Based on this schedule, the study drug was packaged
and labelled for each subject. Subject randomisation
numbers were pre-printed on the labels and assigned
sequentially as subjects were recruited. The randomisation
was stratified by investigator site, achieved by issuing
blocks of consecutive numbers to each site.
The differing nature of the dose forms, with divergent
posology, did not permit a full double-blind design. A
single-blinded approach (with investigators blind to treat-
ment group) was adopted to minimise potential bias during
data collection and evaluation of clinical endpoints. Study
medication was presented in sealed cartons of identical
appearance, differing only in the allocation code. Each
recruited subject was sequentially allocated the next
available number.
To maintain the blind, sealed envelopes containing the
study drug identification were provided to the investigator;
these were not used in the course of the study. The allo-
cation code was broken only after all subjects had com-
pleted the study and the database had been locked in order
to perform statistical analysis. Administration of the study
medication was supervised at the site by clinical personnel
not otherwise connected with the study.
2.7 Statistical Methods
All output was produced using Statistical Analysis Soft-
ware (SAS) version 9.1.3 (SAS Institute Inc., Cary, NC,
USA) combined with AdClin (AdClin S.A., Paris,
France).
The test for non-inferiority (NUS 0–24) of loperamide–
simeticone caplets versus tablets was one-sided with a
equal to 0.025; all other tests were two-sided at a 0.05
level.
The efficacy analysis was performed using an intention-
to-treat (ITT) set, which included all randomised subjects,
with imputation for missing efficacy endpoint data. A last
observation carried forward (LOCF) approach was used for
the primary endpoint (NUS 0–24), in this case the baseline
values; for the time-to-event analyses, missing values were
right censored at 48 h; and for subject evaluation of
treatment effectiveness, missing data were replaced with
the most negative outcome of ‘poor’. For the follow-up
endpoints at 7 days, an efficacy set based on all patients
completed was used, with no imputation of data.
An analysis of variance (ANOVA) with effects for
treatment (either loperamide–simeticone caplets or chew-
able tablets) and investigator site was used to derive a one-
sided 97.5 % confidence interval (CI), bounded from
above, for the mean difference between loperamide–
simeticone caplets and chewable tablets with respect to the
primary endpoint (NUS 0–24). Non-inferiority was con-
cluded if the (upper) bound of the one-sided 97.5 % CI was
B0.5, the non-inferiority margin. An ANOVA with effects
for treatment and investigator site was used to construct
two-sided 95 % CIs for the mean differences between the
S. boulardii group and loperamide–simeticone caplet and
chewable tablet groups with respect to NUS 0–24.
Time-to-event analyses (TLUS, TCRD, TCRAD) were
performed pairwise by means of the log-rank test stratified
for investigator site.
For subject’s evaluation of treatment effectiveness for
overall illness relief, diarrhoea relief and abdominal dis-
comfort relief, frequency distributions were compared
pairwise between the three treatment groups using the Chi-
square (v2) test or Fisher’s exact test. For the follow-up
endpoints at 7 days, frequency distributions between the
three treatment groups were compared pairwise using a v2
test (or Fisher’s exact test).
3 Results
Figure 1 shows the flow of subjects through the study. The
first subject’s first visit was on 12 November 2008 and the
last subject’s last visit took place on 30 August 2009. The
demographic (Table 1) and clinical characteristics
366 J. Cottrell et al.
(Table 2) of the subjects enrolled in the three groups were
comparable at baseline. Similar proportions of travellers
and local residents participated: 47 % of subjects were
from Mexico or India, with most international travellers to
these countries originating from either North America
(23 %) or Europe (17 %). The ITT set consisted of 415
(100 %) subjects.
3.1 Primary Endpoint
3.1.1 Number of Unformed Stools (0–24 h)
The primary endpoint was NUS 0–24 following the
initial dose of study medication; results are presented in
Table 3. The mean values were similar between the
Assessed for eligibility (n = 518)
Excluded (n = 103)
♦ Did not meet inclusion criteria 
(n = 93)
♦ Other reasons (n = 10)
ITT analysis (n = 139)
Subjects completed (n = 135)
Lost to follow-up (n = 4)
Loperamide–simeticone caplet (n = 139) Saccharomyces boulardii capsules (n = 137)
ITT analysis (n = 137)








Lost to follow-up (n = 4) Lost to follow-up (n = 5)
ITT analysis (n = 139)
Subjects completed (n = 135)
Fig. 1 Study flow diagram. ITT intention-to-treat







N 139 139 137 415
Age (years)
Mean 36.2 36.1 36.9 36.4
Range 19–72 18–72 19–79 18–79
Sex [n (%)]
Male 93 (67) 81 (58) 93 (68) 267 (64)
Female 46 (33) 58 (42) 44 (32) 148 (36)
Country/region of origin [n (%)]
Mexico 44 (32) 33 (24) 37 (27) 114 (27)
USA/Canada 26 (19) 33 (24) 37 (27) 96 (23)
India 23 (17) 32 (23) 27 (20) 82 (20)
Europe 26 (19) 26 (19) 20 (15) 72 (17)
Russia 11 (8) 6 (4) 13 (9) 30 (7)
South America 4 (3) 4 (3) 2 (1) 10 (2)
Other 5 (4) 5 (4) 0 (0) 11 (3)
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loperamide–simeticone caplet group (3.4) and the chew-
able tablet group (3.3). The (upper) limit of the one-
sided 97.5 % CI for the difference (caplets - tablets) was
0.50, equal to the predetermined non-inferiority margin,
and therefore non-inferiority was concluded. Both lop-
eramide–simeticone groups had a significantly lower
mean NUS 0–24 than the S. boulardii capsule group
(4.3) (both p\ 0.001).
Analysis of the primary endpoint based on all subjects
completed without imputation (n = 403) gave a similar
outcome. In this analysis, mean NUS 0–24 values were 3.3
in the loperamide–simeticone caplet group, 3.2 in the
chewable tablet group and 4.3 in the S. boulardii group.
The (upper) limit of the one-sided 97.5 % CI for the dif-
ference (caplets - tablets) was 0.48, within the predeter-
mined non-inferiority margin.
3.2 Secondary Endpoints
3.2.1 Time to Last Unformed Stool
The estimated median TLUS (Kaplan–Meier analysis)
was significantly longer in the S. boulardii capsule group
(28.5 h) than in either the loperamide–simeticone caplet
(14.9 h) or chewable tablet (14.0 h) groups. There was no
significant difference between loperamide–simeticone
caplets and chewable tablets, while the differences
between both loperamide–simeticone caplets and chew-
able tablets and S. boulardii capsule were significant
(p\ 0.001). The Kaplan–Meier curve for the TLUS is
shown in Fig. 2.
3.2.2 Time to Complete Relief of Diarrhoea
Overall, the median TCRD (Kaplan–Meier analysis) was
significantly longer in the S. boulardii capsule group
(45.8 h) than in both loperamide–simeticone groups (both
26.0 h; p\ 0.001). The loperamide–simeticone caplets
and tablets groups were not significantly different. Figure 3
shows the Kaplan–Meier curve for the TCRD.
3.2.3 Time to Complete Relief of Abdominal Discomfort
Overall, the median TCRAD (Kaplan–Meier analysis) was
significantly longer in the S. boulardii capsule group
(23.9 h) than in the loperamide–simeticone caplet and
chewable tablet groups (12.2 and 12.0 h, respectively;
p\ 0.005). No significant difference between loperamide–
simeticone caplets and chewable tablets was found.
3.2.4 Subject’s Evaluation of Treatment Effectiveness
The proportion of subjects evaluating treatment effective-
ness as ‘very good’ or ‘excellent’ was higher in both the
loperamide–simeticone caplet group (83.5 %) and chew-
able tablet group (85.6 %) than in the S. boulardii capsule
group (48.9 %) for overall illness relief, higher in the
loperamide–simeticone caplet group (79.9 %) and chew-
able tablet group (84.9 %) than in the S. boulardii capsule
group (46.0 %) for diarrhoea relief, and higher in the
loperamide–simeticone caplet group (79.1 %) and chew-
able tablet group (81.3 %) than in the S. boulardii capsule
group (42.3 %) for abdominal discomfort relief.












N 139 139 137 415
Duration of diarrhoeal illness [mean
(h)]a
22.2 21.9 22.7 22.3
Time since last stool [mean (h)]a 1.9 1.9 2.5 2.1
Consistency of last stool [n (%)]b
Grade 2 33 (24) 42 (30) 38 (28) 113 (27)
Grade 3 106 (76) 97 (70) 99 (72) 302 (73)
Mean number of unformed stools in the
past 24 h
5.9 5.4 5.5 5.6
Severe abdominal discomfort [n (%)]c 55 (40) 48 (34) 48 (35) 151 (36)
a Calculated to time of first dose of study medication
b Grade 1 formed, stool retains its shape, Grade 2 soft, stool assumes the shape of a container, Grade 3
liquid, stool can be poured
c None no symptom at all, Mild tolerable, does not interfere with normal activities, Moderate distressing,
forces change in normal activities, Severe incapacitating, prohibits normal activities
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The differences in the response frequencies between the
loperamide–simeticone caplet or chewable tablet and
S. boulardii capsule were statistically significant for all
evaluations of treatment effectiveness (p\ 0.001 in each
case); no significant difference was found between the
loperamide–simeticone caplet and chewable tablet for any
evaluation of treatment effectiveness.
3.2.5 Follow-Up Endpoints
Overall, most subjects (95.3 %) reported passing stool at
least once since the final study visit, with similar propor-
tions across the treatment groups; differences were not
statistically significant (Table 4).
Most subjects (94.3 %) overall did not experience con-
tinued or recurrent diarrhoea after the final study visit. The
proportion of subjects who reported either continuation or a
return of diarrhoea since the final study visit was slightly
higher in the S. boulardii capsule group (5.7 %) than in the
loperamide–simeticone caplet group (3.7 %) and the
loperamide–simeticone chewable tablet group (3.7 %).
Differences between the loperamide–simeticone caplet and
tablet and the loperamide–simeticone tablet and
S. boulardii capsule were not significant, while the differ-
ence between the loperamide–simeticone caplet and
S. boulardii capsule was significant (p\ 0.03).
Most subjects reported feeling completely well at the
follow-up evaluation (loperamide–simeticone caplets and
tablets 96.3 %; S. boulardii capsules 88.6 %). The differ-
ences between both loperamide–simeticone groups and the
S. boulardii capsule were statistically significant (p\ 0.02).
3.3 Tolerability
A total of 17 (4.1 %) subjects experienced at least one
adverse event; three (2.2 %) subjects in the loperamide–
simeticone caplet group, seven (5.0 %) subjects in the
loperamide–simeticone chewable tablet group and seven
(5.1 %) subjects in the S. boulardii capsule group. The
most commonly reported adverse events were nausea,








N 139 139 137
Number of unformed stools 0–24 h
(mean)
3.4 3.3 4.3 One-sided 97.5 % CI (tablets–
caplets): -0.50 to infinity
Two-sided 95 % CI (S. boulardii–
caplets): 0.43–1.22
Two-sided 95 % CI (S. boulardii–
tablets: 0.55–1.34
Time to last unformed stool [median
(h)]
14.9 14.0 28.5 Caplet vs. tablet, p = 0.82
Caplet vs. S. boulardii, p\ 0.001
Tablet vs. S. boulardii, p\ 0.001
Time to complete relief of diarrhoea
[median (h)]
26.0 26.0 45.8 Caplet vs. tablet, p = 0.50
Caplet vs. S. boulardii, p\ 0.001
Tablet vs. S. boulardii, p\ 0.001
Time to complete relief of abdominal
discomfort [median (h)]
12.2 12.0 23.9 Caplet vs. tablet, p = 0.98
Caplet vs. S. boulardii, p\ 0.005
Tablet vs. S. boulardii, p\ 0.005
Subject’s evaluation of treatment (% very good or excellent)
Overall illness relief 83.5 85.6 48.9 Caplet vs. tablet, p = 0.45
Caplet vs. S. boulardii, p\ 0.001
Tablet vs. S. boulardii, p\ 0.001
Diarrhoea relief 79.9 84.9 46.0 Caplet vs. tablet, p = 0.12
Caplet vs. S. boulardii, p\ 0.001
Tablet vs. S. boulardii, p\ 0.001
Abdominal discomfort relief 79.1 81.3 42.3 Caplet vs. tablet, p = 0.85
Caplet vs. S. boulardii, p\ 0.001
Tablet vs. S. boulardii, p\ 0.001
CI confidence interval
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asthenia and anorexia [in three (0.7 %) subjects each,
overall]. Constipation was reported by two (1.4 %) subjects
in the loperamide–simeticone chewable tablet group, with
no reports in the other two groups. No subject experienced
a serious adverse event or was withdrawn from the study


















































































Fig. 3 Time to complete relief of diarrhoea (Kaplan–Meier curve)
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4 Discussion
This acute diarrhoea study was conducted in Mexico and
Goa, India, areas with a high risk for acute diarrhoea, and
included a mixed population of adult residents, expatriates
and international travellers. TD is usually defined in studies
as the passage of at least three unformed stools within a
24-h period, accompanied by at least one gastrointestinal
symptom. Subjects in this study would meet this definition
on clinical criteria, though by convention TD usually refers
to acute diarrhoea that develops in a resident of the
industrialised world who travels to a developing tropical or
semitropical country. TD is most usually of bacterial ori-
gin, with enterotoxigenic Escherichia coli (ETEC) the
major pathogen in most cases worldwide [22]. There are,
however, geographical differences, with ETEC dominating
in Latin America, while Campylobacter jejuni and Sal-
monella spp. are more important in Asian countries. Sim-
ilar enteropathogens are also responsible for acute endemic
diarrhoeas, although in residents the clinical course is
milder [23]. In this study there was no attempt to identify a
causative pathogen at the time of inclusion in the study.
The treatments in this study were non-specific, and forms
of clinical presentation that would have required further
investigation (particularly persistent and dysenteric diar-
rhoea) were entry exclusions. Diagnostic yield is low using
conventional laboratory methodologies, with no pathogen
identified in up to half of cases [22]. Future studies may
benefit from the use of PCR (polymerase chain reaction)
diagnostic techniques for intestinal pathogens, which offers
the advantages of increased sensitivity and greater
timeliness of diagnosis [24]. Although the cause of acute
diarrhoea was not determined in this study, 52 % of the
sample were international travellers to the study countries
and it is probable on the basis of previous epidemiological
studies that most cases were bacterial in origin.
Two previous double-blind, randomised studies
demonstrated that the loperamide–simeticone chewable
tablet was significantly more effective than either lop-
eramide or simeticone alone or placebo over a 48-h study
period [8, 9]. This study has demonstrated that the caplet
form of the loperamide–simeticone combination was non-
inferior in comparison with the original chewable tablet
with respect to the primary endpoint of NUS 0–24, with
means of 3.4 and 3.3 for the caplet and tablet, respectively.
There were no statistically significant differences between
the two formulations for any of the secondary endpoints,
which supports the finding of non-inferiority for the pri-
mary endpoint. The two formulations show very similar
efficacy and can therefore be considered clinically
equivalent.
As a non-inferiority study, the design could be criticised
for not including a placebo arm. However, guidelines [25]
allow for an active-controlled non-inferiority design where
there is sufficient demonstration of efficacy in well-con-
ducted placebo-controlled studies [8, 9].
This study also compared the loperamide–simeticone
combinations versus probiotic yeast capsules (S. boulardii).
Previously no clinical trial has compared loperamide with a
probiotic, and a formulation of S. boulardii capsule with a
licensed indication for treatment of acute diarrhoea was
selected for this study.
Table 4 Follow-up evaluation
at 7 days (all patients completed












N 135 136 132
Passed stool (C1) since
final study visit (%)
94.1 94.8 97.0 Caplet vs. tablet, p = 0.80
Caplet vs. S. boulardii,
p = 0.25





3.7 3.7 5.7 Caplet vs. tablet, p = 0.50
Caplet vs. S. boulardii,
p\ 0.03





96.3 96.3 88.6 Caplet vs. tablet, p = 1.000
Caplet vs. S. boulardii,
p\ 0.02
Tablet vs. S. boulardii,
p\ 0.02
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The effect of S. boulardii has been investigated in the
treatment and prevention of various forms of diarrhoeal
diseases, with evidence of efficacy particularly in children
and in more persistent diarrhoea, usually with an endpoint
of reduced duration [12–21]. Although a meta-analysis of
studies showed evidence of efficacy for S. boulardii in the
prevention of TD [15], evidence for efficacy in treatment is
lacking. There appears to be only one published study [26]
investigating treatment of TD, in which S. boulardii was
used to treat travellers in Tunisia. Subjects with TD were
randomised to 600 mg of S. boulardii (1 9 1010/day) for
5 days or an active control treatment. Of 60 subjects
enrolled, 43 completed the trial, but the duration of diar-
rhoea was not significantly different between those given
S. boulardii (2.1 days) and those given ethacridine lactate
and tannalbuminate (1.4 days). In our study, the
S. boulardii capsule used at the approved dose of 250 mg
twice daily was significantly less effective than the lop-
eramide–simeticone formulations for all primary and sec-
ondary endpoints. This suggests that there may be more of
a role for S. boulardii in diarrhoea in children, more per-
sistent diarrhoea or in prevention than in treatment of acute
diarrhoea in adults.
Previous studies with loperamide–simeticone [8, 9] have
not followed subjects beyond 48 h after the initial dose. In
this study, follow-up at 7 days was obtained remotely. As
expected for a self-limiting condition, most subjects felt
completely well following their diarrhoeal illness, though
the proportions were significantly higher with both lop-
eramide–simeticone formulations than with the S. boulardii
capsule. Continued or recurrent diarrhoea was reported by
a small minority of subjects in each group; slightly fewer
with the loperamide–simeticone formulations than with the
S. boulardii capsule. At 7-day follow-up more than 94 % of
subjects reported passing stool at least once since the
second study visit (i.e. between 4 and 5 days after visit 2),
with no significant differences between the groups. In
addition, there were two adverse event reports of consti-
pation, both of which were in the loperamide–simeticone
chewable tablet group (1.4 %). This supports findings from
other well-controlled double-blind trials of acute diarrhoea
that normal dosing schedules of loperamide are not asso-
ciated with a significant incidence of constipation or con-
stipation-like episodes.
5 Conclusions
In this study, the loperamide–simeticone caplet formulation
was demonstrated to be non-inferior to the original chew-
able tablet formulation; both formulations can be expected
to demonstrate similar clinical efficacy in the relief of
symptoms of acute diarrhoea. Both formulations of
loperamide–simeticone were consistently superior to the
S. boulardii capsule with regards to the primary and sec-
ondary endpoints.
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